Trial · NCT01153425
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 28
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Moderate | Gastrointestinal disorders | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | Gastrointestinal disorders | Zoledronic Acid (Reclast) | 1 | 17 | 1 |
| other | Moderate | General disorders | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | General disorders | Zoledronic Acid (Reclast) | 2 | 17 | 2 |
| other | Moderate | Blood and lymphatic system disorders | Teriparatide (Forteo) | 2 | 16 | 3 |
| other | Moderate | Blood and lymphatic system disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Eye disorders | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Eye disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Skin and subcutaneous tissue disorders | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Skin and subcutaneous tissue disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Skin and subcutaneous tissue disorders | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Skin and subcutaneous tissue disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Surgical and medical procedures | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | Surgical and medical procedures | Zoledronic Acid (Reclast) | 1 | 17 | 1 |
| other | Moderate | Skin and subcutaneous tissue disorders | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | Skin and subcutaneous tissue disorders | Zoledronic Acid (Reclast) | 1 | 17 | 1 |
| other | Moderate | Surgical and medical procedures | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Surgical and medical procedures | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Mild | Blood and lymphatic system disorders | Teriparatide (Forteo) | 7 | 16 | 9 |
| other | Mild | Blood and lymphatic system disorders | Zoledronic Acid (Reclast) | 6 | 17 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01153425/events